Tyche Industries
BSE: TYCHE · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Tyche Industries's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Tyche Industries Limited is an Indian pharmaceutical company specialising in the manufacturing of Active Pharmaceutical Ingredients (APIs), intermediates, and nutraceuticals. The company operates a manufacturing facility in Kakinada and focuses on therapeutic segments including anti-diabetic, anti-hypertensive, and anti-convulsant agents.
Business Model
The company generates revenue through the production and sale of niche chemical molecules and custom synthesis services for the global generic pharmaceutical supply chain. It leverages cost-effective production processes and international regulatory compliance to maintain its competitive market position.
Growth Outlook
Growth is driven by ongoing investments in research and development to enhance chemical synthesis capabilities. The company aims to expand its footprint by focusing on high-value niche molecules within the global pharmaceutical market.
Key Risks
- Regulatory Compliance. Failure to maintain international regulatory standards at manufacturing facilities could lead to export restrictions or loss of market access.
- Raw Material Price Volatility. Fluctuations in the cost of key starting materials and chemical intermediates can significantly impact profit margins.
- Intense Competition. The generic pharmaceutical sector is highly competitive, potentially leading to pricing pressures that affect the company's profitability.
- Foreign Exchange Risk. As an entity serving international markets, the company is exposed to currency fluctuations that may impact export revenue.
Start your research today
Unlock AI insights, financials, peers and live data on Tyche Industries and 5,000+ companies — free.
Key Metrics
REVENUE
₹54 Cr
TTM · standalone
NET PROFIT
₹7 Cr
TTM · standalone
EPS
₹6.69
TTM · standalone
RETURN ON EQUITY
5.0%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
6.8%
TTM · standalone
P/E
19.4x
Q4 FY26 · standalone
EV/EBITDA
9.4x
Q4 FY26 · standalone
EBITDA MARGIN
21.4%
TTM · standalone
NET PROFIT MARGIN
7.1%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Tyche IndustriesTYCHE | ₹107 Cr | 15.67 | 8.88 | -18.9% | 21.4% | 5.0% | 6.8% | -21.5% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q4 FY26
Financials
Tyche Industries
BSE: TYCHE · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Tyche Industries's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Tyche Industries Limited is an Indian pharmaceutical company specialising in the manufacturing of Active Pharmaceutical Ingredients (APIs), intermediates, and nutraceuticals. The company operates a manufacturing facility in Kakinada and focuses on therapeutic segments including anti-diabetic, anti-hypertensive, and anti-convulsant agents.
Business Model
The company generates revenue through the production and sale of niche chemical molecules and custom synthesis services for the global generic pharmaceutical supply chain. It leverages cost-effective production processes and international regulatory compliance to maintain its competitive market position.
Growth Outlook
Growth is driven by ongoing investments in research and development to enhance chemical synthesis capabilities. The company aims to expand its footprint by focusing on high-value niche molecules within the global pharmaceutical market.
Key Risks
- Regulatory Compliance. Failure to maintain international regulatory standards at manufacturing facilities could lead to export restrictions or loss of market access.
- Raw Material Price Volatility. Fluctuations in the cost of key starting materials and chemical intermediates can significantly impact profit margins.
- Intense Competition. The generic pharmaceutical sector is highly competitive, potentially leading to pricing pressures that affect the company's profitability.
- Foreign Exchange Risk. As an entity serving international markets, the company is exposed to currency fluctuations that may impact export revenue.
Start your research today
Unlock AI insights, financials, peers and live data on Tyche Industries and 5,000+ companies — free.
Key Metrics
REVENUE
₹54 Cr
TTM · standalone
NET PROFIT
₹7 Cr
TTM · standalone
EPS
₹6.69
TTM · standalone
RETURN ON EQUITY
5.0%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
6.8%
TTM · standalone
P/E
19.4x
Q4 FY26 · standalone
EV/EBITDA
9.4x
Q4 FY26 · standalone
EBITDA MARGIN
21.4%
TTM · standalone
NET PROFIT MARGIN
7.1%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26